Skip to main content

Advertisement

SpringerLink
Log in

ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Advanced age is considered an unfavourable prognostic factor for Hodgkin’s lymphoma (HL). The optimal treatment for these patients is not yet defined, especially for the advanced stages. We analysed the outcome and prognostic relevance of patient and disease characteristics in 46 advanced stage HL patients who were older than 45 years, treated with ABVD. Elderly patients (>60 year) had a significantly higher rate of comorbidities (p < 0.05). The complete remission rate was significantly lower in elderly patients and in patients with an IPS ≥3 (p < 0.05, p < 0.05, respectively). Elderly patients had significantly shorter event-free survival (p < 0.01) and overall survival (p < 0.01) compared to patients of 45–60 year. Extranodal disease, an IPS ≥3, bulky disease, an ESR > 50 and the presence of a large mediastinal tumour mass didn’t have an influence on survival (p > 0.05). The multivariate Cox regression analysis identified the age of >60 year as an independent prognostic factor. The prospective clinical trials seem to be needed for defining the optimal therapeutic approach in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brusamolino E, Bacigalupo A, Barosi G et al (2009) Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 94:550–565

    Article  PubMed  Google Scholar 

  2. Klimm B, Engert A (2009) Combined modality treatment of Hodgkin’s lymphoma. Cancer J 15:143–149

    Article  PubMed  CAS  Google Scholar 

  3. Klimm B, Diehl V, Engert A (2007) Hodgkin’s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park) 21:982–990, discussion 990, 996, 998 passim

    Google Scholar 

  4. Peterson BA, Pajak TF, Cooper MR et al (1982) Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep 66:889–898

    PubMed  CAS  Google Scholar 

  5. Specht L, Nissen N (1989) Hodgkin’s disease and age. Eur J Haematol 43:127–135

    Article  PubMed  CAS  Google Scholar 

  6. Bosi A, Ponticelli P, Casini C et al (1989) Clinical data and therapeutic approach in elderly patients with Hodgkin’s disease. Haematologica 74:463–473

    PubMed  CAS  Google Scholar 

  7. Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB (1995) Outcome of Hodgkin’s disease in elderly patients. Hematol Oncol 13:19–27

    Article  PubMed  CAS  Google Scholar 

  8. Klimm B, Eich HT, Haverkamp H et al (2007) Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18:357–363

    Article  PubMed  CAS  Google Scholar 

  9. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. N Engl J Med 339:1506–1514

    Article  PubMed  CAS  Google Scholar 

  10. Levis A, Anselmo AP, Ambrosetti A et al (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15:123–128

    Article  PubMed  CAS  Google Scholar 

  11. Wedelin C, Bjorkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H (1984) Prognostic factors in Hodgkin’s disease with special reference to age. Cancer 53:1202–1208

    Article  PubMed  CAS  Google Scholar 

  12. Eghbali H, Hoerni-Simon G, de Mascarel I, Durand M, Chauvergne J, Hoerni B (1984) Hodgkin’s disease in the elderly. A series of 30 patients aged older than 70 years. Cancer 53:2191–2193

    Article  PubMed  CAS  Google Scholar 

  13. Enblad G, Glimelius B, Sundstrom C (1991) Treatment outcome in Hodgkin’s disease in patients above the age of 60: a population based study. Ann Oncol 2:297–302

    PubMed  CAS  Google Scholar 

  14. Guinee VF, Giacco GG, Durand M et al (1991) The prognosis of Hodgkin’s disease in older adults. J Clin Oncol 9:947–953

    PubMed  CAS  Google Scholar 

  15. Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB (1992) Hodgkin’s disease in the elderly. A registry-based analysis. Cancer 70:830–834

    Article  PubMed  CAS  Google Scholar 

  16. Levis A, Depaoli L, Urgesi A et al (1994) Probability of cure in elderly Hodgkin’s disease patients. Haematologica 79:46–54

    PubMed  CAS  Google Scholar 

  17. Forsyth PD, Bessell EM, Moloney AJ, Leach IH, Davies JM, Fletcher J (1997) Hodgkin’s disease in patients older than 70 years of age: a registry-based analysis. Eur J Cancer 33:1638–1642

    Article  PubMed  CAS  Google Scholar 

  18. Landgren O, Algernon C, Axdorph U et al (2003) Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438–444

    PubMed  Google Scholar 

  19. Levis A, Depaoli L, Bertini M et al (1996) Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin’s disease patients. Haematologica 81:450–456

    PubMed  CAS  Google Scholar 

  20. Zinzani PL, Magagnali M, Bendandi M et al (2000) Efficacy of VBM regimen in the treatment of elderly patients with Hodgkin’s disease. Haematologica 85:729–732

    PubMed  CAS  Google Scholar 

  21. Austin-Seymour MM, Hoppe RT, Cox RS, Rosenberg SA, Kaplan HS (1984) Hodgkin’s disease in patients over 60 years old. Ann Intern Med 100:13–18

    PubMed  CAS  Google Scholar 

  22. Canellos GP, Anderson JR, Propert K et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    Article  PubMed  CAS  Google Scholar 

  23. Duggan DB, Petroni GR, Johnson JL et al (2003) Randomized comparison of ABVD and MOPP/ABVD hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614

    Article  PubMed  CAS  Google Scholar 

  24. Gobbi PG, Levis A, Chisesi T et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin’s lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198–9207

    Article  PubMed  CAS  Google Scholar 

  25. Johnson PW, Radford JA, Cullen MH et al (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom lymphoma group. LY09 trial. J Clin Oncol 23:9208–9218

    Article  PubMed  CAS  Google Scholar 

  26. Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 346:1417–1418

    Article  PubMed  Google Scholar 

  27. Federico M, Luminari S, Iannitto E et al (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27:805–811

    Article  PubMed  Google Scholar 

  28. Hoskin PJ, Lowry L, Horwich A et al (2009) Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 27:5390–5396

    Article  PubMed  Google Scholar 

  29. Weekes CD, Vose JM, Lynch JC et al (2002) Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20:1087–1093

    Article  PubMed  CAS  Google Scholar 

  30. Borchmann P, Engert A (2010) The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010:101–107

    Article  PubMed  Google Scholar 

  31. Ballova V, Rüffer JU, Haverkamp H et al (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16:124–131

    Article  PubMed  CAS  Google Scholar 

  32. Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608

    Article  PubMed  Google Scholar 

  33. Raemaekers J, Kluin-Nelemans H, Teodorovic I et al (2002) The achievements of the EORTC lymphoma group. European organisation for research and treatment of cancer. Eur J Cancer 38(Suppl 4):S107–S113

    Article  PubMed  Google Scholar 

  34. Böll B, Borchmann P, Topp MS et al (2010) Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 148:480–482

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Hematology, Clinical Center of Serbia, 2 Koste Todorovic St, 11000, Belgrade, Serbia

    Bosko M. Andjelic, Biljana S. Mihaljevic & Ljubomir R. Jakovic

  2. Faculty of Medicine, University of Belgrade, 8 Dr Subotica St, 11000, Belgrade, Serbia

    Biljana S. Mihaljevic

Authors
  1. Bosko M. Andjelic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Biljana S. Mihaljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ljubomir R. Jakovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bosko M. Andjelic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andjelic, B.M., Mihaljevic, B.S. & Jakovic, L.R. ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years. Pathol. Oncol. Res. 18, 675–680 (2012). https://doi.org/10.1007/s12253-011-9494-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9494-4

Keywords

Search

Navigation